Background: To investigate the effects of different radiotherapy regimens on the prognosis of patients with brain metastases. Materials and Methods: Patients with brain metastases undergoing radiotherapy from January 2016 to December 2020 were retrospectively analyzed. The patients were divided into a whole-brain radiotherapy (WBRT) group, stereotactic ablative radiotherapy (SABR) group, and WBRT+SABR group, and overall survival (OS) and progression-free survival (PFS) were analyzed. Results: Forty patients were candidates for the analysis, with a median age of 57. 5 years and a median follow-up time of 27. 4 months. The median OS and PFS were 35. 7 and 13. 5 months, respectively, and the median radiotherapy dose was 41. 7 Gy. The median OS times for patients who received WBRT (n = 12), SABR (n = 21), and WBRT+SABR (n = 7) were 41. 8, 70. 6, and 56. 8 months, respectively (p = 0. 7). The median PFS times were 10. 2 months, 34. 3 months, and 25. 9 months, respectively (p = 0. 322). Subgroup analysis indicated that the OS times were 25. 4 months after WBRT (n = 7), 79. 1 months after SABR (n = 11), and 65. 9 months after WBRT+SABR (n = 5) among patients with brain metastases from lung cancer (p = 0. 028). The patients had PFS times of 7. 1, 33. 4, and 29. 1 months after irradiation with WBRT, SABR, and combination therapy, respectively (p = 0. 009). Conclusion: The three different radiotherapy regimens had no significant effects on the prognosis of patients with brain metastases. SBAR was superior to WBRT and WBRT+SABR with respect to the prognosis of patients with brain metastases from lung cancer. The sample size of this retrospective study was small,therefore, larger, prospective studies are needed.